Insulin Downregulates the Transcriptional Coregulator CITED2, an Inhibitor of Proangiogenic Function in Endothelial Cells

Diabetes 2016;65:3680–3690 | DOI: 10.2337/db16-0001

In patients with atherosclerotic complications of diabetes, impaired neovascularization of ischemic tissue in the myocardium and lower limb limits the ability of these tissues to compensate for poor perfusion. We identified 10 novel insulin-regulated genes, among them Adm, Cited2, and Ctgf, which were downregulated in endothelial cells by insulin through FoxO1. CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2), which was downregulated by insulin by up to 54%, is an important negative regulator of hypoxia-inducible factor (HIF) and impaired HIF signaling is a key mechanism underlying the impairment of angiogenesis in diabetes. Consistent with impairment of vascular insulin action, CITED2 was increased in cardiac endothelial cells from mice with diet-induced obesity and from db/db mice and was 3.8-fold higher in arterial tissue from patients with type 2 diabetes than control subjects without diabetes. CITED2 knockdown promoted endothelial tube formation and endothelial cell proliferation, whereas CITED2 overexpression impaired HIF activity in vitro. After femoral artery ligation, induction of an endothelial-specific HIF target gene in hind limb muscle was markedly upregulated in mice with endothelial cell deletion of CITED2, suggesting that CITED2 can limit HIF activity in vivo. We conclude that vascular insulin resistance in type 2 diabetes contributes to the upregulation of CITED2, which impairs HIF signaling and endothelial proangiogenic function.

Coronary artery and peripheral vascular disease are major complications of diabetes. In these atherothrombotic diseases, angiogenesis is an important component in the complex response to acute and chronic ischemia. Diabetes is characterized by an impaired ability of hypoxic tissues to improve perfusion through angiogenesis (1). This impairment is caused by reduced activation of hypoxia-inducible factor (HIF), changes in growth factor signaling, abnormalities in inflammation accompanying the response to ischemia, and changes in mobilization and function of bone marrow–derived proangiogenic cells (1). There is obvious potential benefit from improving perfusion without, or in addition to, surgical intervention. However, despite efficacy of several strategies to improve angiogenesis in animal models of diabetes (1), there is no
established clinical pharmacological approach to improve angiogenesis in diabetes.

Insulin resistance is a central feature of type 2 diabetes (2). Insulin can promote angiogenesis by upregulating expression of vascular endothelial growth factor (VEGF) (3,4). In addition, insulin can act directly on vascular endothelial cells to promote angiogenesis. Knockout of the insulin receptor in endothelial cells in a mouse model of oxygen-induced retinopathy caused a pronounced reduction of retinal neovascularization, with the number of preretal cells reduced by 57% (5). This reduction of retinal angiogenesis is similar in magnitude to the effect of anti-VEGF therapy in the same mouse model (6). Therefore, insulin resistance in endothelial cells may contribute to the impaired neovascular response to ischemia in obesity and type 2 diabetes.

Knowledge about the downstream effectors of the proangiogenic action of insulin on vascular endothelium is mostly limited to regulation of nitric oxide (NO) (7). Increased synthesis of NO (8–11) is one of the most established actions of insulin in endothelial cells, and NO is a critical mediator of angiogenesis (12). Insulin increases endothelial-derived NO through phosphorylation of endothelial NO synthase (eNOS) by Akt and by increasing expression of eNOS (2,9). Consistent with this mechanism, the bioavailability of endothelial-derived NO is decreased in patients with diabetes (13,14).

Insulin also acts as a potent inhibitor of FoxO transcription factors in many cell types, and endothelial cell FoxO has an angiostatic role in postnatal vascular homeostasis and angiogenesis (15,16). We therefore decided to investigate the ability of insulin to regulate 21 direct FoxO targets previously implicated in angiogenesis. These candidates were identified in adult mice harboring an inducible Cre transgene and “floxed” genes for the three major FoxO isoforms, FoxO1, 3, and 4 (16). The triple knockout mice developed hemangiomas in the uterus, liver, and skeletal muscle. The authors of this study hypothesized that genes that were differentially expressed in endothelial cells from hemangioma-prone and hemangroma-resistant vascular beds were driving proangiogenic function (16). Using gene array analysis, gene expression was measured in endothelial cells cultured from hemangioma-prone liver and compared with gene expression in endothelial cells from lung, which was not susceptible to the development of hemangioma. The promoter regions of genes differentially regulated in liver compared with lung endothelial cells were then searched for FoxO target sequences. In the majority of genes selected previously described (21). Primer sequences are shown in Supplementary Table 1. Real-time PCR and Western blotting were performed as previously described (21). Primer sequences are shown in Supplementary Table 1. CITED2 Western blotting of mouse endothelial cells is downregulated by insulin and increased in insulin resistance and type 2 diabetes in animals and humans. We demonstrate that CITED2 inhibits endothelial cell HIF transactivation and propose that inhibition of CITED2 may improve angiogenesis in type 2 diabetes. In addition, the novel insulin-regulated gene program described here holds potential for further exploration of treatment targets in vascular complications of diabetes.

RESEARCH DESIGN AND METHODS

Additional methods are described in the Supplementary Data.

Animals

Mice with a floxed mutation in the Foxo1 gene (16) were provided by Dr. Domenico Accili (Columbia University). Conditional knockout mice with gene deletion in vascular endothelial cells were generated by breeding mice with a Cre transgene under control of the VE-cadherin (Cdhs5) promoter (stock number 006137; The Jackson Laboratory) (18) with Ins2cre mice (19) or Cited2fl/fl mice (20). db/db mice and age-matched db/+ mice from the same colony were purchased from The Jackson Laboratory (stock number 00697).

Cell Culture

Primary mouse lung, liver, or myocardial endothelial cells were isolated and cultured as described previously (21). MS1 endothelial cells were purchased from the American Type Culture Collection and cultured in DMEM containing 5% FBS. Human umbilical vein endothelial cells (HUVECs) (Lonza) were cultured in EGM-2 medium (Lonza). HUVECs were used between passages two and five.

Human Mammary Artery Biopsies

Human mammary artery tissue was harvested from patients with type 2 diabetes or control subjects without diabetes undergoing coronary artery bypass grafting. Tissue left over from preparing the arterial graft was collected in the operating room and periadventitial tissue quickly removed. Parts of the cleaned vessel were either fixed in formalin or flash frozen. Immunohistochemistry of human arteries was performed on sections of paraffin-embedded tissue using a rabbit polyclonal antibody against CITED2 (catalog no. 7067; ProSci) after antigen retrieval by boiling in citrate buffer.

Adenovirus

Adenoviral constructs expressing mouse wild-type FoxO1 or a constitutively active T24A/S253D/S316A FoxO1 triple mutant were provided by Dr. Domenico Accili (22).

Real-time PCR and Western Blotting

Real-time PCR and Western blotting were performed as previously described (21). Primer sequences are shown in Supplementary Table 1. CITED2 Western blotting of mouse and human cells and tissue was performed using a polyclonal rat CITED2 antibody (catalog no. MAB5005; R&D Systems). In experiments where samples were prepared in several batches, the control conditions were set at 100% in individual experiments and therefore have no error estimates.
Transfection of HUVECs With Plasmids and Small interfering RNA
To overexpress CITED2, HUVECs were transfected with a plasmid containing the full-length cDNA of the human CITED2 gene, a gift from Dr. Shoumo Bhattacharya (17) (plasmid no. 48184; Addgene). The backbone vector pcDNA 3.1 (Invitrogen) was used as a control. A plasmid expressing hypoxia-regulated element (HRE)–luciferase was a gift from Navdeep Chandel (23) (plasmid no. 26731; Addgene). For knockdown of CITED2, a small interfering (siRNA) with the sense sequence 5′-UGC AGA AGC UCA ACA ACC AdTdT-3′ was used. An siRNA targeting a nonmammalian gene (eGFP) was used as a control.

Flow Cytometry and FACS
Flow cytometry of endothelial cells in culture was done after trypsin treatment to produce single-cell suspensions, stained with antibodies, and analyzed on an LSRII instrument (BD Biosciences). For FACS, the ventricles of the heart or both gastrocnemius muscles were minced with scalpels and then dissociated for 1 h in DMEM containing 2 mg/mL (560 units/mL) collagenase I (Worthington), 3 mg/mL Dispase (Roche), and 0.2 mg/mL (400 Kunitz units/mL) DNase I (Millipore). Filtered cells were stained with antibodies and sorted on a MoFlo Legacy (Cytomation, currently Beckman Coulter) or BD FACS Aria II SORP (BD Biosciences). Additional detail is described in the Supplementary Data.

Tube Formation Assay
HUVECs were transfected with CITED2 siRNA or plasmid as described above. After 48 h, cells were trypsin treated and 5,000 cells were plated on Matrigel. Tube formation was photographed through a phase-contrast microscope 4 h later. Images from randomly chosen microscopic fields were selected for analysis and analyzed by Angiogenesis Analyzer for ImageJ (http://image.bio.methods.free.fr/) by an observer unaware of culture conditions. The software automatically analyzes components of endothelial cell tubular networks (Supplementary Fig. 5).

Mouse Hind Limb Surgery
Femoral artery ligation was performed as described previously (24) with modifications as explained in the Supplementary Data.

Ethical Considerations
All protocols for animal use and euthanasia were reviewed and approved by the Animal Care Committee of the Joslin Diabetes Center and were in accordance with National Institutes of Health guidelines. The study of discarded arterial tissue from patients undergoing coronary artery bypass surgery was approved by the regional ethical committee in Denmark (Region Syddanmark, ID S-20100044) and a protocol was submitted to the Danish Data Protection Agency (Datatilsynet) as required by Danish law.

Statistical Analysis
Comparisons were made using paired Student t test for the cell culture studies and unpaired Student t test or Wilcoxon rank-sum test for the clinical data and animal studies, with \( P < 0.05 \) considered statistically significant. In text and graphs, data are presented as the mean \( \pm \) SEM.

RESULTS
Identification of Insulin-Regulated FoxO1 Target Genes
Our aim was to discover novel insulin-regulated genes in endothelial cells with a role in angiogenesis. In the study by Paik et al. (16) described above, results were derived from analysis of endothelial cells from FoxO1/3/4 knockout mice. However, the described proangiogenic phenotype was prominent in FoxO1 knockout mice, whereas knockout of FoxO3, FoxO4, or both in combination did not result in susceptibility to hemangioma formation. Therefore, we reasoned that genes altered by FoxO1 knockout alone were more likely to have potent angiogenic function.

Endothelial cells were isolated from livers of Foxo1lox/lox mice by two rounds of immunomagnetic isolation. The cultures were then infected with an adenovirus expressing
Cre recombinase or a control adenovirus. The proportion of CD31+ cells was 97.0 ± 0.4 and 98.2 ± 0.3%, respectively, in recombined and control cultures (Supplementary Fig. 1A). This demonstrated a high purity of endothelial cells given that CD31+ cells costained for other endothelial markers, including VE-cadherin and VEGF receptor 2 (KDR) (Supplementary Fig. 1B and C). Cre-mediated recombination resulted in complete deletion of FoxO1 at the protein level without changes in FoxO3 or FoxO4 protein expression (Fig. 1A). FoxO1 knockout significantly changed expression of Adm, Ctgf, Fbn1, Hmga2, Klf6, Noct (also known as Ccrn4l), Pbx1, Spry2, and Tcf4 (Fig. 1C). These candidates were further studied as described below. Among the remaining genes, Cnd1, Meis1, Mrc1, Sdpr, Selrn, and Tsc22d1 were not regulated (Fig. 1C), whereas Brmp, Id1, Pcolce, and Rab34 were regulated in the opposite direction of the change previously reported in cells cultured from Foxo1/3/4 knockout mice (16). Nrep (known as D0h4s114 or P311) was not detected.

In FoxO1-knockout cells, insulin receptor substrate-1 (IRS-1) and IRS-2 mRNA decreased by 73 ± 7 and 57 ± 2% (data not shown), and IRS-1 and IRS-2 protein decreased by 38 ± 12 and 75 ± 6% (Fig. 1B). These results are similar to previously published results describing that IRS-1 and IRS-2 are decreased in aortic endothelial cells from mice with endothelial-specific deletion of FoxO1/3/4 (25). Consequently, a knockout approach would not be useful to prove involvement of FoxO1 in insulin-stimulated signaling. We therefore used adenoviral vectors to express wild-type FoxO1, a constitutively active FoxO1 mutant or a control virus. It seemed important to study a wide time range of exposure to insulin as we expected the effect to be transient and the expression kinetics to differ for each gene. Because it was not feasible to expand primary mouse endothelial cells to include all control conditions at several time points, we used MS1 endothelial cells, which we have previously shown are sensitive to insulin (21). Cultures were serum starved overnight and treated with 10 nmol/L insulin for 2, 4, 8, or 16 h. mRNA expression results are shown in Fig. 2 for the time point with the largest change in the nontransfected condition.

Among the 10 genes selected, all were regulated by insulin (Fig. 2). We considered typical FoxO-dependent regulation to exist if insulin and FoxO caused reciprocal gene regulation and if insulin counteracted a change induced by wild-type FoxO1 overexpression but not one induced by overexpression of the constitutively active FoxO1 mutant. The expression of Adm, Ctgf, and Cited2 was downregulated in insulin in a typical FoxO-dependent manner (Fig. 2A–C). Klf6, Spry2, and Tcf4 were three independent experiments are shown. *P < 0.05, compared with no insulin in the same condition with respect to adenovirus infection; †P < 0.05, compared with insulin-un-treated GFP condition.

**Figure 2**—Gene regulation by FoxO1 and insulin in endothelial cells. A–J: MS1 endothelial cells were mock infected (No) or infected with adenovirus vectors expressing GFP (GFP), wild-type FoxO1 (wt), or a FoxO1 mutant made constitutively active by Ser to Ala mutations at three residues phosphorylated by Akt (CA). After 48 h, including serum starvation overnight, cells were stimulated with insulin (10 nmol/L, dark gray bars) or left untreated (light gray bars) for 2, 4, 8, or 16 h. RNA was isolated from cell lysate and analyzed by real-time PCR. For each gene, results from the time point with the largest insulin response are shown. All values are expressed relative to nontransfected controls. Mean values from
downregulated by insulin but were not changed by FoxO overexpression (Fig. 2E–G). Pbx1 was upregulated by insulin but was not changed by FoxO1 overexpression (Fig. 2I). Insulin also increased Noct, but this regulation may not be mediated through FoxO1 because Noct was increased by both FoxO1 expression and insulin treatment and the mutant FoxO1 did not prevent insulin regulation (Fig. 2H). Fbn1 and Hmgaa2 were regulated by insulin and ectopic FoxO1 expression in opposite directions, as expected (Fig. 2D and J), but these changes were not concordant with regulation after FoxO1 knockout in liver endothelial cells (Fig. 1C). Selection of genes for further study based on the criteria above is outlined in Supplementary Fig. 1.

Among the genes with typical regulation, Ctgf was downregulated by 80 ± 1% after 2 h, Cited2 by 60 ± 1% after 2 h, and Adm by 54 ± 2% after 16 h (Fig. 2A–C). Ctgf encodes connective tissue growth factor (CTGF), a secreted protein that is a key effector of transforming growth factor-β signaling (26,27). Cited2 encodes a transcriptional coregulator discussed extensively below, and Adm encodes adrenomedullin, a circulating vasodilator peptide hormone that is highly expressed in endothelial cells and vascular smooth muscle cells (28,29).

Ctgf, Cited2, and Adm were all expressed in endothelial cells freshly isolated from gastrocnemius muscle from C57BL/6 mice, although endothelial cell levels of Ctgf were relatively low compared with nonendothelial cells (Supplementary Fig. 2). CTGF and adrenomedullin are secreted by a number of cell types, and the importance of endothelial-derived CTGF and adrenomedullin relative to nonendothelial sources is uncertain. In contrast, the

Figure 3—Features of insulin-dependent regulation of CITED2 in endothelial cells. A–K: MS1 endothelial cells were serum starved overnight and then treated with IGF1 (G) or insulin (all other panels) at a final concentration of 10 nmol/L unless otherwise indicated. RNA was isolated from cell lysate and analyzed by real-time PCR. Protein expression was measured in cell lysate by Western blotting. Mean values from three or four experiments are shown. *P < 0.05. A–D: Cells were treated for 2 h (B) or the duration listed. E and F: Cultures were treated with the insulin receptor antagonist S961 for 1 h followed by 10 nmol/L insulin for 8 h. G: Cultures were treated with IGF1 for 2 h. H and I: Cells were stably transfected with a lentiviral construct expressing a short hairpin RNA targeting the IGF1 receptor gene (shigf1r) and treated with insulin for 2 h (I). J and K: MS1 endothelial cells were serum starved overnight and then treated with the PI3K or Akt inhibitor LY294002 or MK2206, respectively, for 30 min, followed by treatment with 10 nmol/L insulin for 2 h, as indicated.
function of CITED2 as a transcriptional coregulator is cell autonomous. In addition, HIF is a key regulator of endothelial biology (30–33) and CITED2 has been shown to regulate HIF in nonvascular cells (17). As such, insulin-regulation of CITED2 in endothelial cells is likely important for endothelial function. Therefore, we proceeded by studying CITED2 to test our paradigm that genes regulated by insulin through FoxO are likely to be dysregulated in type 2 diabetes where vascular insulin signaling is impaired.

**CITED2 Is Regulated by Insulin Through the Insulin Receptor, PI3K, and Akt**

Insulin downregulated CITED2 mRNA with a nadir at 2 h in time-course experiments (Fig. 3A). The effect of insulin was potent and concentration dependent, with reductions in CITED2 mRNA of 31 ± 12, 55 ± 6, and 59 ± 7% by 1, 10, and 100 nmol/L insulin for 2 h (Fig. 3B). At the protein level, the maximal effect of insulin occurred after 8 h, where CITED2 was downregulated by 54 ± 13% (Fig. 3C and D).

The insulin receptor antagonist S961 efficiently blocked insulin-induced phosphorylation of Akt (Supplementary Fig. 3A) and prevented reduction of CITED2 protein after insulin treatment (Fig. 3E and F). Insulin-like growth factor-1 (IGF1) at 10 nmol/L reduced CITED2 mRNA by 48 ± 5%, with no additional effect at 100 nmol/L (Fig. 3G). After RNAi-mediated downregulation of IGF1 receptor (IGF1R) protein to 91 ± 4% of control levels (Fig. 3H), insulin reduced CITED2 mRNA as efficiently as in control cells (Fig. 3I). These results demonstrate that although both insulin and IGF1 can reduce CITED2, the effect of insulin is mediated by the insulin receptor as opposed to the IGF1R. Treating endothelial cells with the PI3K inhibitor LY294002 or the Akt inhibitor MK2206 blocked insulin-stimulated downregulation of CITED2 mRNA (Fig. 3J–K). Therefore, insulin-stimulated downregulation of CITED2 is dependent on the insulin receptor, PI3K, Akt, and FoxO1. Exposure to high glucose concentrations for 72 h did not change the magnitude of insulin-induced downregulation of CITED2 compared with an osmotic control or low glucose concentrations (Supplementary Fig. 3B and C).

Next, we examined how CITED2 was regulated in endothelial cells in a vascular bed relevant to the vascular complications of diabetes. We isolated mouse myocardial endothelial cells by immunomagnetic isolation. In myocardial endothelial cells from control mice, insulin decreased CITED2 protein by 48 ± 9%, but in mice with endothelial-specific knockout of the insulin receptor, insulin had no effect (Fig. 4A and B).

Endothelial cell insulin signaling through the PI3K/Akt pathway is impaired in animal models of obesity-associated insulin resistance (34,35). We therefore measured the expression of CITED2 mRNA in freshly isolated endothelial cells from mice with diet-induced obesity and from db/db mice. Cardiac ventricles were enzymatically dissociated and single-cell suspensions separated by FACS. This sorting process yielded viable cells, and CD45+ cells and then selected for CD31+ and CD45− cells. This sorting process yielded viable cells, and CD45+ cells and then selected for CD31+ and CD45− cells. Next, we examined how CITED2 was regulated in endothelial cells from control mice, insulin decreased CITED2 protein by 48 ± 9%, but in mice with endothelial-specific knockout of the insulin receptor, insulin had no effect (Fig. 4A and B).

**Figure 4**—CITED2 expression in mouse myocardial endothelial cell culture, freshly isolated mouse cardiac endothelial cells, and human mammary arteries. A and B: Myocardial endothelial cells were isolated from mice with deletion of the insulin receptor gene (Insr) targeted to endothelial cells [Tg(Cre) InsrL/L] or their controls (Insr+/+). Cultures were serum starved overnight and then treated with 10 nmol/L insulin for 4 h. Protein expression was measured in cell lysate by Western blotting. A: Representative immunoblots. B: Quantitative analysis based on densitometry from three independent experiments. C and D: Mouse heart ventricles were enzymatically digested and sorted by FACS. Sequential gating excluded debris, doublets and aggregates, nonviable cells, and CD45+ cells and then selected for CD31+ and CD31− cells. C: Real-time PCR was performed on samples from four mice on a regular low-fat diet and four mice on a high-fat diet. D: Real-time PCR was performed on samples from four db/+ mice and three db/db mice. E and F: Human mammary artery tissue was obtained during coronary artery bypass surgery from five male obese patients with type 2 diabetes and four male nonobese control subjects without diabetes. Clinical characteristics are listed in Table 1. Artery left over after trimming the graft was immediately isolated from perivascular tissue and fixed in formalin (for histology) or frozen (for protein lysate). E: Protein expression was measured in tissue lysate by Western blotting. F: Quantitative analysis based on densitometry. *P < 0.05.
resulted in efficient isolation of endothelial cell markers; in CD45−CD31+ cells from the heart of db/+ control mice, the endothelial cell markers Pecam1 and Kdr were 35.5 ± 1.3-fold and 50.8 ± 0.6-fold higher, respectively, than in CD45−CD31− cells (Supplementary Fig. 4A and B). In CD45−CD31+ cardiac cells isolated from mice on a high-fat diet, CITED2 mRNA was increased to 159 ± 6% of the level in mice on a low-fat diet (Fig. 4C). Similarly, in CD45−CD31+ cardiac cells from db/db mice, CITED2 mRNA was increased to 187 ± 19% of the level in db/+ mice (Fig. 4D). There was no difference in CITED2 mRNA in CD45−CD31− cells in mice on a low-fat versus a high-fat diet or in db/db versus db/+ mice (Fig. 4C and D).

We next measured expression of CITED2 in vascular tissue from obese patients with type 2 diabetes compared with age-matched patients without obesity or diabetes. Insulin signaling through the PI3K/Akt pathway is impaired in patients with metabolic syndrome with insufficient compensation by hyperinsulinemia (2). We therefore expected increased expression of CITED2 in these patients. We collected mammary arteries from five obese patients with diabetes and four patients without obesity or diabetes undergoing coronary artery bypass surgery (Table 1). Patients in both groups had an average age of 61 years (Table 1). BMI was 35.9 ± 3.4 kg/m² in the group of patients with diabetes and 26.2 ± 0.9 kg/m² in control subjects. Lipid profiles were similar between both groups, consistent with the fact that all patients in both groups were treated with statins. There was a nonsignificant trend toward higher systolic and diastolic blood pressure in the group without diabetes despite the fact that all patients were treated with antihypertensive therapy. Immunohistochemistry of CITED2 revealed weak staining throughout the vascular wall but intense staining in nuclei of endothelial cells (Supplementary Fig. 4C). In tissue lysate, CITED2 was 3.8-fold higher in obese patients with diabetes than in the group without diabetes (P = 0.003 by Student t test; P = 0.04 by Wilcoxon rank-sum test) (Fig. 4E and F). These data, in a limited sample of patients, suggest that CITED2 is upregulated in vascular tissue in patients with obesity and type 2 diabetes and is consistent with the previous demonstration that patients with type 2 diabetes exhibit endothelial cell insulin resistance (13,14). Importantly, this difference is maintained despite near optimal control of hemoglobin A₁c (HbA1c), blood pressure, and plasma lipids in patients with diabetes and suggests a potential therapeutic benefit of CITED2 inhibition.

**CITED2 Regulates Endothelial Proangiogenic Function and HIF Transactivation**

Having demonstrated that CITED2 is upregulated in endothelial cells in diabetes, we next sought to examine the significance of these changes by characterizing the effects of CITED2 in endothelial cells. We used HUVECs for these experiments because human endothelial cells perform better in tube formation assays than primary rodent endothelial cells (36). As in MS1 endothelial cells (Fig. 3) and primary mouse myocardial endothelial cells (Fig. 4A and B), insulin decreased CITED2 protein in HUVECs (Fig. 5A). After 8 h of insulin treatment, CITED2 was 44% of control levels (Fig. 5B). HUVECs were transfected with siRNA targeting CITED2, which produced efficient knockdown with 95% reduction of CITED2 protein at 50 nmol/L siRNA (Fig. 5C). Compared with HUVECs transfected with a control siRNA, HUVECs with CITED2 knockdown increased several measures of tube formation on Matrigel (Fig. 5D and E and Supplementary Fig. 5). We then labeled HUVECs with EdU in order to determine the rate of DNA synthesis, a measure of cell proliferation (Fig. 5F and G). Knockdown of CITED2 increased EdU incorporation by 2.1 ± 0.3-fold (Fig. 5G). We therefore conclude that CITED2 negatively affects tube formation and suppresses proliferation of endothelial cells.

CITED2 has been shown to regulate HIF transactivation in a number of cell types (17), but this effect has not been described in any vascular cells, including endothelial cells. Demonstration of this specific phenomenon is important because CITED2 can both activate and inhibit transcription factors by restricting the availability of CBP/p300 or by acting as a molecular scaffold recruiting these coactivators to the transcription factor complex. This effect must be measured by HIF transactivation rather than DNA binding. We therefore used a luciferase

| Table 1—Patient characteristics |
|----------------------------------|
| **No diabetes** | **Type 2 diabetes** | **P** |
| **Mean ± SEM** | **Mean ± SEM** |    |
| Age (years) | 61.7 ± 3.7 | 61.6 ± 4.5 | 0.99 |
| BMI (kg/m²) | 26.2 ± 0.9 | 35.9 ± 3.4 | 0.02 |
| HbA₁c (%) | 5.6 ± 0.0 | 7.0 ± 0.0 | 0.03 |
| Systolic blood pressure (mmHg) | 147.0 ± 6.2 | 134.4 ± 6.1 | 0.15 |
| Diastolic blood pressure (mmHg) | 81.4 ± 3.9 | 72.0 ± 3.9 | 0.10 |
| Total cholesterol (mmol/L) | 4.1 ± 0.4 | 4.3 ± 0.5 | 0.82 |
| LDL cholesterol (mmol/L) | 2.2 ± 0.3 | 2.0 ± 0.3 | 0.53 |
| HDL cholesterol (mmol/L) | 1.2 ± 0.2 | 1.0 ± 0.1 | 0.38 |
reporter with a promoter containing hypoxia-regulated elements (HREs). Expression of this reporter in HUVECs showed that overexpression of CITED2 (Fig. 6A) decreased HRE-related activity by 59 ± 6% (Fig. 6B). Therefore, CITED2 impairs HIF transactivation in endothelial cells and inhibits endothelial proangiogenic function.

To establish that CITED2 regulates HIF in endothelial cells in vivo, we generated mice with cre-mediated recombination of the Cited2 gene (20) after cross-breeding with Cdh5-Cre transgenic mice. In primary lung endothelial cells cultured from Tg(Cre) Cited2lox/lox mice, CITED2 protein was reduced by 70 ± 6% compared with endothelial cells cultured from Cited2lox/lox control mice (Fig. 6C). We studied these animals during hind limb ischemia after ligation of the femoral artery on one side.

We measured endothelin-1 (Edn1) mRNA in muscle lysate. Endothelin-1 is a HIF target gene (37) and is involved in angiogenesis (38). It is also expressed preferentially in endothelial cells, which we validated by measuring expression in nonischemic gastrocnemius muscle enzymatically dissociated and sorted by FACS. Edn1 was 24.2 ± 3.2-fold higher in CD31+ cells than in CD31− cells (Fig. 6D). Therefore Edn1 serves as a model HIF target gene specifically expressed in endothelial cells that can be used to assay changes in endothelial HIF activity in whole tissue lysate. HIF-1α is among the most short-lived proteins with a half-life of a few minutes after restoration of normoxia after hypoxia (39), and HIF target genes are similarly short-lived with Edn1 mRNA half-life being less than half an hour (33). We therefore measured Edn1 in lysate from flash-frozen muscle. Edn1 was increased in ischemic hind limb gastrocnemius muscle from C57BL/6 mice 24 h after femoral artery ligation (Supplementary Fig. 6). Expression subsequently decreased at 2, 3, and 7 days after surgery (Supplementary Fig. 6). In Cited2lox/lox control mice, Edn1 increased by 2.7 ± 0.4-fold in the ischemic compared with the nonischemic leg (Fig. 6E). However, in Tg(Cre) Cited2lox/lox mice, there was a 4.1 ± 0.4-fold induction in Edn1 (P = 0.02, compared with induction in Cited2lox/lox control mice) (Fig. 6E). This result indicates that CITED2 suppresses endothelial cell HIF transactivation in hypoxia and supports the concept that induction of CITED2 may contribute to dysfunction of HIF in type 2 diabetes.

**DISCUSSION**

Diabetes remains a risk factor for cardiovascular disease (40) despite control of plasma glucose, lowering of LDL cholesterol, and treatment of hypertension (41). Therefore, there is a need to reduce cardiovascular risk by targeting other factors that are dysregulated in diabetes.
Insulin resistance in vascular endothelial cells is one such target. For example, we have previously shown that loss of insulin signaling in endothelial cells increases atherosclerosis in apolipoprotein E-null mice by up to threefold without changes in glucose tolerance, plasma lipids, or blood pressure (21). Insulin resistance in endothelial cells may also impair angiogenesis (5) and contribute to cardiovascular risk independent of atherosclerosis. However, little is known of the proangiogenic effector mechanisms that are activated by insulin in endothelial cells. Genes with angiogenic or angiostatic action that are regulated by insulin in endothelial cells are likely dysregulated in conditions with insulin resistance and may contribute to the impaired response to hypoxia. The identification of such genes can provide novel targets for improvement of angiogenesis in obesity and type 2 diabetes.

With the results presented here, we have identified novel insulin-regulated genes in endothelial cells. They were selected by a combined genetic and functional filter. Importantly, they were differentially regulated in endothelial cells by deletion of FoxO in tissues prone to hemangioma formation in FoxO-knockout animals (16). Therefore, they have a high likelihood of being mechanistically involved in endothelial cell homeostasis and angiogenesis. We validated this notion by demonstrating that one of these genes, CITED2, is downregulated by insulin in primary mouse and human endothelial cells and upregulated in cardiac endothelial cells isolated from obese animals and in vascular tissue from patients with obesity and type 2 diabetes. Furthermore, in keeping with predicted antiangiogenic function, CITED2 limits HIF transactivation in endothelial cells and negatively regulates endothelial cell tube formation and proliferation.

Although we did not study the other nine insulin-regulated genes further, we have provided a valuable resource for further study of the mechanisms leading from insulin resistance in endothelial cells to dysfunctional angiogenesis. These genes were not previously reported to be regulated by insulin, although one of them, the transcription factor Klf6, was shown to be upregulated by IGF1 (42). Several of the genes have previously been associated with angiogenic function, including Ctgf (26,27), Adm (28,29), Pbx1 (43), Spry2 (44), and Tcf4 (45). However, a direct role for Fbn1, Hmga2, Klf6, and Noct in angiogenesis has not been demonstrated.

Our rationale for further exploring the role of CITED2 was that one of the best-described functions of CITED2 is negative regulation of HIF-1α (17). Expression of CITED2 is induced by HIF-1α. In turn, CITED2 inhibits HIF-1α transactivation by competing with the transactivation domain of HIF-1α for both p300 and CREB binding protein (CBP) (46). Activation of endothelial cell HIF is critical for angiogenesis. Deletion of HIF-1β (Arnt) (30) or targeting both HIF-α isoforms (31) specifically in endothelial cells results in failure of vascular development and embryonic lethality. HIF-α isoforms have overlapping specificity but distinct function, and both HIF-1α (32) and HIF-2α (33) are necessary for normal angiogenesis in adulthood. Insulin may function as a proangiogenic factor through negative regulation of CITED2, thereby releasing a regulatory brake on HIF-dependent transcription.

Consistent with the ability of insulin to suppress CITED2 expression, this gene is upregulated in animal models and humans with insulin resistance. Expression of CITED2 is increased in liver of mice with diet-induced obesity or with the db/db mutation (47). More importantly, in gene array analysis...
of skeletal muscle biopsies, CITED2 was one of the most downregulated genes during a euglycemic-hyperinsulinemic clamp in healthy volunteers (48). This was confirmed in an independent, unbiased screen of insulin-stimulated gene expression in skeletal muscle (49). In contrast, CITED2 was much less reduced during clamp in patients with type 2 diabetes than in healthy control subjects (48). Downregulation of hepatic CITED2 in mice limits gluconeogenesis and improves glucose tolerance (47). It is therefore possible that inhibition of CITED2 may improve both insulin sensitivity and angiogenesis. Given recent assertions that therapies for type 2 diabetes should be tested for efficacy in modifying cardiovascular morbidity or mortality alongside their glucoregulatory actions (50), CITED2 is an attractive therapeutic target.

With our study, we have identified a group of endothelial genes that are controlled by insulin through FoxO1 and are likely dysregulated in insulin resistance. One of these genes, CITED2, is upregulated in vascular tissue in patients with obesity and type 2 diabetes and suppresses HIF transactivation and proangiogenic function in endothelial cells. These results advance our understanding of insulin action on endothelial cells and points to new therapeutic approaches to improve angiogenesis in patients with obesity and type 2 diabetes.

Acknowledgments. The authors thank Dr. C. Ronald Kahn of the Joslin Diabetes Center for providing Foxo1lox/lox mice from a colony maintained by his laboratory.

Funding. X.W. received grants from the National Natural Science Foundation of China (81370936) and the Shanghai Pujiang Program (16PJ1401700). S.M.L. was supported by a Non-Clinical Open Funding Programme from the Diabetes Center for providing Nordisk through the STAR Programme. C.R.-M. receives research support from Novo Nordisk Foundation. B.T.O. was supported by National Institute of Diabetes Diseases grant U24 DK076169. The authors thank Dr. C. Ronald Kahn of the Joslin Diabetes Center for providing Foxo1lox/lox mice from a colony maintained by his laboratory.

Duality of Interest. T.R. was an employee of Novo Nordisk and was supported by the STAR Programme. C.R.-M. receives research support from Novo Nordisk through the STAR Programme.

Author Contributions. X.W. and S.M.L. performed most of the experiments and edited the manuscript. T.R., H.A., D.S., and N.D. contributed to experiments and edited the manuscript. B.T.O. bred Foxo1lox/lox mice and edited the manuscript. S.P.R., H.C.B., and L.M.R. contributed to collection of human arterial tissue and discussion and editing of the manuscript. S.L.D. generated Cited2 floxed mice. M.T.W. edited the manuscript. C.R.-M. oversaw experiments and drafted the manuscript. C.R.-M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Some of these results have been presented in abstract form at the 75th Scientific Sessions of the American Diabetes Association, Boston, MA, 5–9 June 2015, and the 76th Scientific Sessions of the American Diabetes Association, New Orleans, LA, 10–14 June 2016 (abstract number 1882-P and 1737-P, respectively).

References
1. Howangyin KY, Silvestre JS. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arterioscler Thromb Vasc Biol 2014;34:1126–1135
2. Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2012;32:2052–2059
3. Lu M, Amano S, Miyamoto K, et al. Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci 1999;40:3281–3286
4. Jiang ZY, He Z, King BL, et al. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 2003;278:31964–31971
5. Kondo T, Vicent D, Suzuma K, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 2003;111:1835–1842
6. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457–10461
7. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013;14:5–12
8. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894–898
9. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000;101:676–681
10. Duncan ER, Crossey PA, Walker S, et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo [published correction appears in Diabetes 2009;58:511]. Diabetes 2008;57:3307–3314
11. Tabot CE, Shenouda SM, Holbrook M, et al. Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 2013;127:86–95
12. Yu J, deMunck ED, Zhuang Z, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A 2005;102:10999–11004
13. Steinberg HD, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601–2610
14. Rask-Madsen C, Ihlemann N, Krarup T, et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 2001;50:2611–2618
15. Potente M, Urbich C, Sasaki K, et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 2005;115:2382–2392
16. Paik JH, Kollipara R, Chu G, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007;128:309–323
17. Bhatchacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, Livingston DM. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 1999;13:64–75
18. Alva JA, Zovein AC, Monvoisin A, et al. VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn 2006;235:759–767
19. Brüning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559–569
20. Preis J, Wise N, Solloway MJ, Harvey RP, Sparrow DB, Dunwoodie SL. Generation of conditional Cited2 null alleles. Genesis 2006;44:579–583
21. Raek-Madsen C, Li Q, Freund B, et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab 2010;11:379–389
22. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhrl) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001;108:1359–1367
23. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 2008;105:2622–2627
24. Peck MA, Crawford RS, Abularrage CJ, et al. A functional murine model of hindlimb demand ischemia. Ann Vasc Surg 2010;24:532–537
25. Tsuchiya K, Tanaka J, Shuijing Y, et al. FoxO5 integrates pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab 2012;15:372–381
26. Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999;19:2958–2966
27. Hall-Glenn F, De Young RA, Huang BL, et al. CCN2/connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis. PLoS One 2012;7:e30562
28. Tokunaga N, Nagaya N, Shirai M, et al. Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: benefits of a novel nonviral vector, gelatin. Circulation 2004;109:526–531
29. Iimuro S, Shindo T, Moriyama N, et al. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 2004;95:415–423
30. Yim SH, Shah Y, Tomita S, et al. Disruption of the Arnt gene in endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab 2000;15:372–381
31. Licht AH, Müller-Hillbamp F, Flamm I, Breier G. Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development. Blood 2006;107:584–590
32. Tang N, Wang L, Esko J, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485–495
33. Skuli N, Liu L, Runge A, et al. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 2009;114:469–477
34. Jiang ZY, Lin YW, Clement A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999;104:457–467
35. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011;13:294–307
36. Simons M, Altalal K, Annex BH, et al.; American Heart Association Council on Basic Cardiovascular Sciences and Council on Cardiovascular Surgery and Anesthesia. State-of-the-art methods for evaluation of angiogenesis and tissue vascularization: A scientific statement from the American Heart Association. Circ Res 2015;116:e99–e132
37. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem 2001;276:12645–12653
38. Salani D, Taraboletti G, Rosanò L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157:1703–1711
39. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510–5514
40. Gerstein HC, Miller ME, Genuith S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818–828
41. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet 2010;376:958]. Lancet 2010;375:2215–2222
42. Bentov I, Narla G, Schayek H, et al. Insulin-like growth factor-1 regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology 2008;149:1890–1897
43. Charbonneau A, East L, Mulholland N, Rohde M, Boudreau N. Pbx1 is required for Hox D3-mediated angiogenesis. Angiogenesis 2005;8:289–296
44. Taniguchi K, Sasaki K, Watari K, et al. Suppression of Sproutys has a therapeutic effect for a mouse model of ischemia by enhancing angiogenesis. PLoS One 2009;4:e5467
45. Jiang L, Yin M, Wei X, et al. Bach1 represses Wnt/b-catenin signaling and angiogenesis. Circ Res 2015;117:364–375
46. Freedman SJ, Sun ZY, Kung AL, France DS, Wagner G, Eck MJ. Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat Struct Biol 2003;10:504–512
47. Sakai M, Matsumoto M, Tujimura T, et al. CITED2 links hormonal signaling to PGC-1alpha acetylation in the regulation of gluconeogenesis. Nat Med 2012;18:612–617
48. Asmann YW, Stump CS, Short KR, et al. Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia. Diabetes 2006;55:3309–3319
49. Coletta DK, Balas B, Chavez AO, et al. Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo. Am J Physiol Endocrinol Metab 2008;294:E910–E917
50. Naci H, Lehrman R, Wouters OJ, Goldacre B, Yudkin JS. Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ 2015;351:h5260